High-Dose Flu Vaccine Offered Additional Protection Against Influenza, Pneumonia Hospitalization Among Adults Aged 50 To 64 Compared To Standard-Dose Vaccine, Study Finds

Healio (12/15, Feller) reported, “A recombinant influenza vaccine offered additional protection against PCR-confirmed influenza and community-acquired pneumonia hospitalization among adults aged 50 to 64 years compared with a standard-dose vaccine, study results showed.” In the study, published in the New England Journal of Medicine, among “patients aged between 50 years and age 64 years, 559 participants (or two cases per 1,000) tested positive for influenza in the recombinant vaccine group compared with 925 (2.34 cases per 1,000) positive tests in the standard dose group, for a relative vaccine effectiveness against influenza infection of 15.3%.”